Sign in

    Daniel Hurren

    Healthcare Analyst at MST Marquee

    Dan Hurren is a Healthcare Analyst at MST Marquee, specializing in equity research on the healthcare sector with coverage of leading companies such as ResMed Inc., Integral Diagnostics, Neuren Pharmaceuticals, Ansell Ltd, Capitol Health, EBOS Group, Fisher & Paykel Healthcare, and others. He has established a strong performance reputation, having partnered with Andrew Goodsall as the #1 ranked healthcare research team from 2004 to 2014 at Citi and UBS, and later served as head of the UBS Australian Sales Desk in Singapore for six years. Hurren began his financial services career after serving 15 years as an Australian Regular Army Officer, and he holds a Bachelor of Arts from the University of New South Wales and a Masters of International Studies from Sydney University. He is an authorised representative of Health Finance Group Pty Ltd under MST Financial and continues to be recognized for in-depth knowledge and leadership in healthcare equity research.

    Daniel Hurren's questions to RESMED (RMD) leadership

    Daniel Hurren's questions to RESMED (RMD) leadership • Q1 2025

    Question

    Daniel Hurren inquired about ResMed's M&A priorities, the potential scale of "tuck-in" acquisitions given its debt capacity, and the overall capital management strategy.

    Answer

    CEO Michael Farrell highlighted successful tuck-ins like Snap and Somnoware that add digital capabilities. CFO Brett Sandercock defined "tuck-in" as potentially up to $500 million and outlined the capital priorities as R&D investment, tuck-in M&A, and an increasing quarterly share buyback program.

    Ask Fintool Equity Research AI